

Greater Manchester Joint Formulary & RAG/DNP list change log

05 August 2022



The list below includes changes made in the last 12 months. For information on older updates, contact nuth.enquiries.gmmmg@nhs.net

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
05/08/2022	6	6.4.1	Note added: "Section under review; GMMMG HRT guidance is in development"	n/a	Y	9.9
05/08/2022	7	7.2.1	Note added: "Section under review; GMMMG HRT guidance is in development"	n/a	Y	7.1
27/07/2022	2	2.12	Wording updated to indicate that "An NHSE/NHS Digital tool to aid identification of eligible patients is available for some primary care clinical systems (EMIS / SystemOne). A GM Case Record finding tool will be available from Health Innovation Manchester shortly."	Y	Y	7.8
27/07/2022	2	2.9	Links to NICE guidance and MHRA Drug Safety Updates re-formatted for clarity. Broken links to MHRA DSUs for prasugrel (hypersensitivity reactions, May 2011) and clopidogrel (risk of haemophilia, Dec 2013) corrected. Links to MHRA DSUs for prasugrel (risk of bleeding, Jan 2014) and clopidogrel (omeprazole interaction, April 2010) added.	n/a	Y	7.8
25/07/2022	2	2.12	Following wording now outdated, and has been removed: "The pricing structure agreed by NHSE/I means the NICE approved cost can only be accessed in primary care."	Y	Y	7.7
25/07/2022	4	4.6	Sativex added as RED, in line with NICE NG144: Cannabis-based medicinal products	Y	Y	9.10
22/07/2022	4	4.10.1	Chlordiazepoxide updated to GREEN	Y	Y	9.9
22/07/2022	4	4.7.4.2	Links to NICE TA631 (fremanezumab for preventing migraine) removed and replaced to updated NICE TA764.	Y	Y	9.9
22/07/2022	6	6.1.2.2	MHRA DSU link added: Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk	n/a	Y	9.8
22/07/2022	6	6.4.1.1	Added links to information on managing disruptions to HRT supplies.	n/a	Y	9.8
22/07/2022	RAG	10	Tofacitinib for JIA added to paediatric RAG list as RED	Y	n/a	n/a
22/07/2022	RAG	13	Secukinumab for psoriasis added to paediatric RAG list as RED	Y	n/a	n/a
22/06/2020	4	4.7.4	Updated to correct typos and add section on tension headache. Simple analgesics (paracetamol, aspirin, NSAIDs) added as per 4.7.4.1. Amitriptyline added for prophylaxis.	n/a	Y	9.8
17/06/2022	1	1.6.4	Restriction to macrogol 3350 removed, and statement added directing prescribers to choose the most cost-effective macrogol	n/a	Y	7.2
17/06/2022	2	2.5.2	Moxonidine entry updated to GREEN specialist initiation, to clarify position and align with with standard wording. Previously listed as: "Moxonidine (specialist initiation only)"	Y	Y	7.6
17/06/2022	3	3.4.2	Palforzia added to formulary as RED and GREY, only Only for use in people aged 18 and over if treatment started between the ages of 4 to 17, as per NICE guidance.	Y	Y	8.4
17/06/2022	4	4.7	Whole section updated to align with updated GMMMG headache pathway	Y	Y	9.7
17/06/2022	4	4.7.4.1	Simple analgesics: ibuprofen (OTC), naproxen (unlicensed) and diclofenac (unlicensed) added	Y	Y	9.7
17/06/2022	4	4.7.4.1	Anti-emetics: prochlorperazine added (5mg tabs unlicensed, 3mg buccal tabs OTC)	Y	Y	9.7
17/06/2022	4	4.7.4.1	Combined preparations: aspirin with metoclopramide added. Paracetamol with isometheptene and paracetamol with codeine and buclizine added to DNP list.	Y	Y	9.7
17/06/2022	4	4.7.4.1	Triptans: zolmitriptan, frovatriptan, and rizatriptan tablets added as alternative choices. Zolmitriptan nasal spray added as first choice nasal, if vomiting restricts oral treatment. Nasal sumatriptan retained as alternative nasal.	Y	Y	9.7
17/06/2022	4	4.7.4.2	Alternative options expanded to include: metoprolol (green, specialist advice), topiramate (green, previously required specialist advice), zonisamide (green, specialist advice), amitriptyline, nortriptyline (green, if intolerant to amitriptyline), candesartan (green), flunarazine (red),	Y	Y	9.7
17/06/2022	4	4.7.4.3	Acute treatment: zolmitriptan nasal spray and oxygen added	Y	Y	9.7
17/06/2022	4	4.7.4.3	Prophylaxis: verapamil added (green, specialist advice)	Y	Y	9.7

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
17/06/2022	4	4.7, 4.8	MHRA DSU link added: Pregabalin (Lyrica): findings of safety study on risks during pregnancy	n/a	Y	9.7
17/06/2022	6	6.6.2	MHRA DSU link added: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia	n/a	Y	9.7
17/06/2022	8	8.2.4	Ponesimod for multiple sclerosis added as RED, in line with NICE TA767	Y	Y	12.2
17/06/2022	9	9.1.4	Link added to information on risk of thrombosis on discontinuation of anagrelide	n/a	Y	6.3
17/06/2022	10	10.1.3	Link to NICE TA768 added against upadacitinib	n/a	Y	7.4
17/06/2022	13	13.11.6	Link to NPSA alert on Inadvertent oral administration of potassium permanganate added	n/a	Y	6.1
17/06/2022	13	13.5.2	Brand name and formulation for Calcipotriol 50 micrograms/g, betamethasone dipropionate 0.05% removed from formulary, and replaced with: "Choose the most cost-effective option"	n/a	Y	6.1
17/06/2022	13	13.6.1	Strength of Epiduo gel removed, to align with primary care acne pathway	n/a	Y	6.1
17/06/2022	RAG		Odevixibat added to RAG list as RED, in line with NICE HST17	Y	n/a	n/a
20/05/2022	2	2.12	Bempedoic acid updated to green (specialist advice) from green (specialist initiation)	Y	Y	7.5
20/05/2022	3	3.4.2	Added dupilumab for severe asthma with type 2 inflammation as RED, as per NICE TA751.	Y	Y	8.3
20/05/2022	4	4.4	Solriamfetol for narcolepsy added as a RED drug, as per NICE TA758	Y	Y	9.5
20/05/2022	4	4.4	Modafinil updated to RED pending approval of information for primary care prescribers. Was previously RED pending approval of SCP.	Y	Y	9.5
20/05/2022	4	4.7.3	Section updated to reflect updated GMMMG neuropathic pathway. Added nortriptyline (first line alternative) & capsaicin cream (non-oral alternative) and removed gabapentin for trigeminal neuralgia.	n/a	Y	9.5
20/05/2022	4	4.8.1	Cenobamate for focal onset seizures in epilepsy added as Green (following specialist initiation by a tertiary epilepsy service), as per NICE TA753	Y	Y	9.5
20/05/2022	5	5.3	Sotrovimab added as a RED drug as per NICE NG191	Y	Y	7.3
20/05/2022	6	6.1.2.3	Added link to NG203 (chronic kidney disease) to notes on SGLT2 inhibitors.	n/a	Y	9.6
20/05/2022	9	9.1.4	Added fostamatinib for refractory chronic immune thrombocytopenia to DNP list, as per NICE TA759	Y	Y	6.2
20/05/2022	10	10.2	Risdiplam added as a RED drug as per NICE TA755	Y	Y	7.3
20/05/2022	10	10.1.3	Updated belimumab entry to link to updated NICE guidance, NICE TA752	n/a	Y	7.3
20/05/2022	RAG		Liraglutide for obesity in people aged 12-17 added to DNP list.	Y	n/a	n/a
26/04/2022	3	3.2	Corrected typo on Aectura Breezhaler	n/a	Y	8.1
26/04/2022	3	3.2	Corrected typo on Trixeo Aerosphere	n/a	Y	8.2
21/04/2022	2	2.3.2	MHRA DSU link added: Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision	Y	Y	7.4
21/04/2022	2	2.4 & 2.9	Added link to NICE NG208: heart valve disease presenting in adults	n/a	Y	7.4
21/04/2022	3	3.1 & 3.2	Updated to reflect the GMMMG asthma and COPD management plans	n/a	Y	8.0
21/04/2022	4	4.10.2	Replaced superseded links to NICE NG92 with links to NG209: Tobacco: preventing uptake, promoting quitting and treating dependence	n/a	Y	9.4
21/04/2022	4	4.10.2	Added link to GM tobacco dependency treatment guidelines	n/a	Y	9.4
21/04/2022	6	6.1.2.2	MHRA DSU link added: Metformin in pregnancy: study shows no safety concerns	n/a	Y	9.5
21/04/2022	6	6.1.2.3	Added link to NICE NG28	n/a	Y	9.5
21/04/2022	8	8.2.4	MHRA DSU link added: Cladribine (Mavenclad): new advice to minimise risk of serious liver injury	Y	Y	12.1
21/04/2022	9	9.1	Added crizlizumab as a RED drug, as per NICE TA743	Y	Y	6.1
21/04/2022	9	9.1.1.2	Updated generic name of Monofer to ferric derisomaltose	Y	Y	6.1
21/04/2022	10	10.1.3	Added link to NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis	Y	Y	7.2
21/04/2022	10	10.1.5	Updated link to GM EUR policy, Hyaluronic Acid injections for Osteoarthritis, to latest version	Y	Y	7.2
21/04/2022	RAG		Added givosiran to RAG list as a RED drug, as per NICE HST16	Y	n/a	n/a

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
06/04/2022	6	6.1.2.3	Type 1 diabetes indication for dapagliflozin removed, in line with change to licensed indications and MHRA DSU advice.		Y	9.4
11/03/2022	4	4.2.1	Haloperidol 500 microgram tablets added to DNP list (criterion 2)	Y	Y	9.3
11/03/2022	6	6.1.1.1	Insulin aspart biosimilar (Trurapi) added as first-choice rapid acting insulin analogue in diabetes mellitus	Y	Y	9.3
11/03/2022	RAG		Berotralstat added as RED, in line with NICE TA738	Y	n/a	n/a
09/03/2022	2	2.12	Wording added to bempedoic acid to clarify that it should be used in combination with ezetimibe, in line with NICE TA694	Y	Y	7.3
09/03/2022	3	3.7	MHRA DSU link added: Ivacaftor, tezacaftor, elexacaftor (Kaftrio ▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing	n/a	Y	7.2
09/03/2022	5	5.3	Added molnupiravir as a RED drug, as per NICE NG191	Y	Y	7.2
09/03/2022	5	5.3	MHRA DSU link added: COVID-19 antivirals and pregnancy reporting	Y	Y	7.2
09/03/2022	5	5.4.1	MHRA DSU link added: HCQ & chloroquine risk of CV events & psychiatric reactions	n/a	Y	7.2
09/03/2022	10	10.1.3	MHRA DSU link added: HCQ & chloroquine risk of CV events & psychiatric reactions	Y	Y	7.1
09/03/2022	11	11.8.2.3	MHRA DSU link added: Brolucizumab (Beovu ▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals	Y	Y	5.1
23/02/2022	2	2.8.1	Link to NG191: COVID-19 rapid guideline: managing COVID-19 added against low molecular weight heparins	n/a	Y	7.2
23/02/2022	7	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
23/02/2022	11	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	5.0
23/02/2022	13	13.5.3	Bimekizumab added as RED, in line with NICE TA723	Y	Y	6.0
23/02/2022	13	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	6.0
23/02/2022	RAG		Sapropterin entry updated to add link to TA729.	Y	n/a	n/a
22/02/2022	1	1.3	Link to NG201: antenatal care added (contains advice on heartburn)	n/a	Y	7.1
22/02/2022	3	3.1.4	Link to NG202: obstructive sleep apnoea syndrome added (contains advice on managing rhinitis)	n/a	Y	7.2
22/02/2022	4	4.6	Link to NG201: antenatal care added (contains advice on nausea and vomiting in pregnancy)	n/a	Y	9.2
22/02/2022	4	4.7	Duloxetine 90mg & 120mg capsules added to grey list as GREEN drugs. Criterion 2.	Y	Y	9.2
22/02/2022	6	6.1.1.2	Insulin degludec added as GREY and GREEN (specialist initiation)	Y	Y	9.2
22/02/2022	9	9.1 & 9.5	Links to CG157 & NG8 replaced with link to NG203: Chronic kidney disease: assessment and management	n/a	Y	6.0
22/02/2022	9	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	6.0
22/02/2022	12	12.2.1	Link to NG202: obstructive sleep apnoea syndrome added (contains advice on managing rhinitis)	n/a	Y	5.0
22/02/2022	12	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	5.0
22/02/2022	RAG		Isoniazid for TB prophylaxis in renal patients added as GREEN (specialist initiation)	Y	n/a	n/a
22/02/2022	RAG		Dapsone 50 mg & 100mg tablets for PCP prophylaxis added as GREEN (specialist initiation)	Y	n/a	n/a
20/01/2022	4	Various	MHRA DSU link added to formulary in 4.2.1, 4.2.2, 4.2.3: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium	n/a	Y	9.1
19/01/2022	3	3.2	Links to DHSC information on budesonide in COVID-19 deleted and replaced with link to NICE NG191: Managing COVID-19	n/a	Y	7.1
19/01/2022	5	5.3	Ronapreve added as a RED drug	Y	Y	7.1

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
19/01/2022	6	6.1.1.1	Updated to reflect brand name and specify the insulin for each product, including new brand name for insulin lispro sanofi (Admelog).	n/a	Y	9.1
23/12/2021	8	8.3.4.1	DNP entry for fulvestrant removed pending discussion of appropriate RAG status at next available CRG meeting. DNP status was in line with NICE TAs 209 & 503, however does not reflect TAs 619, 687, 725	Y	Y	12.0
23/12/2021	8	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	12.0
25/11/2021	2	2.12	Inclisiran added to formulary and RAG list as a GREEN drug, with link to TA733 and note that implementation materials are in development.	Y	Y	7.1
17/11/2021	3	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
17/11/2021	4	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	9.0
16/11/2021	1	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
16/11/2021	2	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
12/11/2021	10	10.1.3	Link to NICE TAs 715, 718 & 719 added to formulary	n/a	Y	7.0
12/11/2021	10	10.1.3	MHRA DSU for tofacitinib (Oct 2021) added to formulary, replacing previous HCP letter.	n/a	Y	7.0
12/11/2021	10	All	Following website refresh, chapter updated to amend all links to the GMMMG website to reflect current URLs	n/a	Y	7.0
12/11/2021	RAG		Vortioxetine entry on RAG list aligned with formulary	Y	n/a	n/a
05/11/2021	RAG		Link to NHS Choices resource "supplements: who needs them" deleted, resource no longer available.	Y	n/a	n/a
18/10/2021	1	1.5.2	Budesonide orodispersible tablets (Jorveza) assigned GREEN (following specialist initiation) status, and annotated "as per TA708 only for inducing remission of eosinophilic oesophagitis in adults (treatment duration of up to 12 weeks)."	Y	Y	6.3
18/10/2021	2	2.12	Bempedoic acid assigned GREEN (specialist initiation) RAG status	Y	Y	6.5
18/10/2021	2	2.8.2	Andexanet alfa assigned RED RAG status	Y	Y	6.5
18/10/2021	2	2.8.2	Link to NPSA alert on DOACs and mechanical heart valves added to formulary	n/a	Y	6.5
18/10/2021	4	4.1.1	Melatonin 2mg MR tablets (Circadin) added to formulary as GREEN (following specialist advice) for REM sleep behaviour disorder in Parkinson's disease	Y	Y	8.4
18/10/2021	5	5..3	Remdesivir for COVID-19 added to formulary as a RED drug, in line with NG191	Y	Y	6.2
18/10/2021	6	6.4.1.2	Ulipristal acetate reinstated to formulary as a RED drug, with links to NICE guidance (NG88) and MHRA DSU (Feb 2021)	Y	Y	8.4
18/10/2021	6	6.5.2	Demeclocycline assigned RED RAG status for hyponatraemia associated with SIADH, annotated new patients only from October 2021	Y	Y	8.4
18/10/2021	6	6.6.2	Alendronic acid 70 mg weekly annotated "not licensed for use in men but this is common practice"	Y	Y	8.4
18/10/2021	8	8.2.3	Ofatumumab assigned RED RAG status	Y	Y	11.3
18/10/2021	11	11.2	Link to MHRA DSU on chloramphenicol eye drops for children younger than 2 added	n/a	Y	4.11
18/10/2021	13	13.4	MHRA DSU link added: Topical corticosteroids: information on the risk of topical steroid withdrawal reactions	n/a	Y	5.2
18/10/2021	13	13.6.1, 13.6.2	Link added to NICE NG198: Acne vulgaris: management	n/a	Y	5.2
18/10/2021	13	13.5.1, 13.6.2	MHRA DSU link added: oral retinoids, temporary monitoring advice during COVID-19	Y	Y	5.2

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
18/10/2021	DNP		Deoxycholic acid (Belkyra®) for treatment of moderate to severe convexity or fullness associated with submental fat ("double-chin") in adults assigned DNP status (criterion 1)	Y	n/a	n/a
15/10/2021	10	10.1.3	Guselkumab added to formulary with RED RAG status	n/a	Y	6.4
15/10/2021	RAG		Ravulizumab added to RAG list as a RED drug in line with TA698	Y	n/a	n/a
15/10/2021	RAG		Ravulizumab added to RAG list as a RED drug in line with TA710	Y	n/a	n/a
15/10/2021	RAG		Link to Indigo Gender Service shared care protocol added to leuprorelin, triptorelin, goserelin entries	Y	n/a	n/a
28/09/2021	RAG		Velafaxine: wording updated to clarify that RAG status of green (specialist initiation) only applies for total daily doses of 300 mg or more, and that lower doses are suitable for initiation in primary care.	Y	n/a	n/a
27/09/2021	2	Notes	Text on page 2 corrected to read "NB hypokalaemia can predispose to digitalis toxicity. Caution when used with diuretics."	n/a	Y	6.4
27/09/2021	5	5.1.4	Tobramycin for CF in adults: Amber line deleted, as all patients now repatriated.	Y	Y	6.1
27/09/2021	6	6.1.2.3	Temp RAG status for oral semaglutide updated to permanent decision (green) with grey status removed.	Y	Y	8.3
24/09/2021	RAG		Housekeeping: commissioners harmonised and entries edited for clarity. No changes to any RAG status.	Y	n/a	n/a
24/08/2021	3	3.2	Removed incorrect statement regarding Fostair NEXThaler: "Unlike the pressurised metered dose inhaler Fostair NEXThaler® is not licensed for the management of COPD, or for maintenance and reliever therapy (MART) in adults with asthma."	n/a	Y	6.4
12/08/2021	3	3.4.2	Omalizumab for chronic rhinosinusitis with nasal polyps added to DNP list, in line with NICE TA678	Y	Y	6.3
12/08/2021	9	9.1.4	Temp RAG status for avatrombopag made final (red)	Y	Y	5.2
12/08/2021	9	9.2.1.1	Temp RAG status for patiromer made final (red)	Y	Y	5.2
12/08/2021	10	10.1.3	Temp RAG status for upadacitinib made final (red)	Y	Y	6.3
12/08/2021	10	10.1.3	Temp RAG status for filgotinib made final (red)	Y	Y	6.3
12/08/2021	11	11.8.2.3	Temp RAG status for brolocizuab made final (red)	Y	Y	4.10
12/08/2021	13	13.5.3	Baricitinib assigned RED RAG status	Y	Y	5.1
12/08/2021	RAG		Anakinra added to RAG list as RED, with link to TA685	Y	n/a	n/a
22/06/2020	4	4.7.4	Updated to correct typos and add section on tension headache.	n/a	Y	9.8